Leo Wealth LLC Lowers Holdings in Sanofi $SNY

Leo Wealth LLC cut its stake in shares of Sanofi (NASDAQ:SNY) by 3.8% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 27,342 shares of the company’s stock after selling 1,076 shares during the quarter. Leo Wealth LLC’s holdings in Sanofi were worth $1,321,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of SNY. Cardinal Capital Management increased its position in Sanofi by 0.3% during the 1st quarter. Cardinal Capital Management now owns 69,004 shares of the company’s stock valued at $3,827,000 after purchasing an additional 199 shares during the period. Perigon Wealth Management LLC increased its position in Sanofi by 3.1% during the 1st quarter. Perigon Wealth Management LLC now owns 6,618 shares of the company’s stock valued at $367,000 after purchasing an additional 201 shares during the period. Capital Analysts LLC increased its position in Sanofi by 14.0% during the 1st quarter. Capital Analysts LLC now owns 1,664 shares of the company’s stock valued at $92,000 after purchasing an additional 204 shares during the period. Thomasville National Bank increased its position in Sanofi by 0.3% during the 2nd quarter. Thomasville National Bank now owns 80,440 shares of the company’s stock valued at $3,886,000 after purchasing an additional 211 shares during the period. Finally, Hexagon Capital Partners LLC increased its position in Sanofi by 4.2% during the 1st quarter. Hexagon Capital Partners LLC now owns 5,959 shares of the company’s stock valued at $330,000 after purchasing an additional 238 shares during the period. 14.04% of the stock is currently owned by institutional investors.

Sanofi Price Performance

SNY opened at $48.82 on Friday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.94 and a current ratio of 1.27. The stock has a market capitalization of $119.88 billion, a P/E ratio of 11.74, a P/E/G ratio of 1.19 and a beta of 0.51. The company’s 50-day simple moving average is $48.25 and its two-hundred day simple moving average is $49.87. Sanofi has a 52-week low of $44.62 and a 52-week high of $60.12.

Sanofi (NASDAQ:SNY) last posted its earnings results on Thursday, July 31st. The company reported $0.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.96 by ($0.06). The company had revenue of $11.34 billion for the quarter, compared to the consensus estimate of $9.91 billion. Sanofi had a net margin of 21.47% and a return on equity of 16.86%. Sanofi’s revenue was down 7.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.73 EPS. As a group, analysts predict that Sanofi will post 4.36 EPS for the current year.

Analyst Upgrades and Downgrades

SNY has been the topic of a number of research analyst reports. Weiss Ratings reissued a “hold (c)” rating on shares of Sanofi in a research report on Wednesday. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “hold” rating to a “buy” rating in a research note on Tuesday, September 2nd. Barclays reissued an “overweight” rating on shares of Sanofi in a research note on Wednesday, July 2nd. JPMorgan Chase & Co. raised shares of Sanofi from a “neutral” rating to an “overweight” rating in a research note on Friday, August 8th. Finally, Wall Street Zen raised shares of Sanofi from a “hold” rating to a “buy” rating in a research note on Saturday, August 2nd. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $62.67.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.